Mayer Brown Advises AstraZeneca On Acquisition

Law360, New York (April 23, 2007, 12:00 AM EDT) -- Mayer Brown Rowe & Maw LLP is advising AstraZeneca on the antitrust aspects of its $15.8 billion acquisition of MedImmune Inc., announced on Monday.

The all-cash transaction, in which AstraZeneca would acquire all of MedImmune’s common stock for $58 per share, increases the pharmaceutical giant’s pipeline of biotechnology drugs by 45 projects to 163 projects.

“This acquisition represents a transformational step to deliver our biologics strategy sooner than anticipated,” said David Brennan, chief executive officer of AstraZeneca. “It creates a leading fully integrated biologics and vaccines...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.